US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...
As earnings season begins, filings to the SEC point to uncertainty from the current administration as potential trouble for ...
A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback